Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.50 Consensus PT from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have received a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $17.00.

Several equities analysts have recently issued reports on ATEC shares. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Thursday, August 1st. Stifel Nicolaus decreased their price target on shares of Alphatec from $19.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Wells Fargo & Company cut their price objective on Alphatec from $26.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Morgan Stanley cut Alphatec from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. Finally, Needham & Company LLC reduced their target price on Alphatec from $23.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, August 22nd.

Insider Transactions at Alphatec

In other Alphatec news, Director David M. Demski purchased 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average cost of $5.67 per share, with a total value of $283,500.00. Following the completion of the transaction, the director now owns 288,441 shares of the company’s stock, valued at approximately $1,635,460.47. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 22.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. boosted its stake in shares of Alphatec by 65.2% during the 2nd quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company’s stock valued at $33,365,000 after buying an additional 1,260,137 shares during the period. Magnetar Financial LLC acquired a new stake in Alphatec during the second quarter valued at $10,957,000. Goldman Sachs Group Inc. grew its stake in Alphatec by 93.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,451,499 shares of the medical technology company’s stock valued at $21,932,000 after purchasing an additional 702,950 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in Alphatec by 48.1% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,125,042 shares of the medical technology company’s stock worth $29,305,000 after purchasing an additional 690,022 shares during the last quarter. Finally, Norden Group LLC increased its position in Alphatec by 1,012.2% in the 1st quarter. Norden Group LLC now owns 433,764 shares of the medical technology company’s stock worth $5,982,000 after purchasing an additional 394,763 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Stock Performance

ATEC opened at $5.36 on Tuesday. Alphatec has a 1-year low of $4.88 and a 1-year high of $17.34. The company has a market capitalization of $749.78 million, a price-to-earnings ratio of -3.60 and a beta of 1.39. The business has a 50 day moving average price of $5.83 and a two-hundred day moving average price of $9.07. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Wednesday, July 31st. The medical technology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The firm had revenue of $145.57 million during the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative net margin of 33.48% and a negative return on equity of 816.57%. The company’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.43) EPS. Research analysts predict that Alphatec will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.